| Literature DB >> 26485570 |
Tirza C Hendrik1, Anne F Voor In 't Holt1, Margreet C Vos1.
Abstract
Healthcare-related infections caused by extended-spectrum beta-lactamase (ESBL)-producing Klebsiella spp. are of major concern. To control transmission, deep understanding of the transmission mechanisms is needed. This systematic review aimed to identify risk factors and sources, clonal relatedness using molecular techniques, and the most effective control strategies for ESBL-producing Klebsiella spp. A systematic search of PubMed, Embase, and Outbreak Database was performed. We identified 2771 articles from November 25th, 1960 until April 7th, 2014 of which 148 were included in the systematic review and 23 in a random-effects meta-analysis study. The random-effects meta-analyses showed that underlying disease or condition (odds ratio [OR] = 6.25; 95% confidence interval [CI] = 2.85 to 13.66) generated the highest pooled estimate. ESBL-producing Klebsiella spp. were spread through person-to-person contact and via sources in the environment; we identified both monoclonal and polyclonal presence. Multi-faceted interventions are needed to prevent transmission of ESBL-producing Klebsiella spp.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26485570 PMCID: PMC4617432 DOI: 10.1371/journal.pone.0140754
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flow diagram of study selection for the systematic review and random-effects meta-analyses on extended-spectrum beta-lactamase-producing Klebsiella spp.
1 Number of studies included in the review comprise the sources and reservoirs, associated factors, cluster analysis and successful interventions. 2 No response was obtained from the first and/or corresponding authors for the requested article.
Associated risk factors for the presence of ESBL-producing Klebsiella spp. based on multivariate analyses.
| Associated risk factor | No. of factors | RE | RE or RE range | No. of cases (range) | Studies |
|---|---|---|---|---|---|
| Underlying disease or condition | 17 | OR | 1.04–60.60 | 26–292 |
[
|
| Other antibiotic exposure | 15 | OR | 1.55–95.21 | 10–292 |
[
|
| 1 | HR | 4.60 | 206 |
[
| |
| Length of hospital stay | 11 | OR | 1.05–12.60 | 18–80 |
[
|
| 1 | HR | 1.26 | 206 |
[
| |
| Medical devices | 9 | OR | 2.11–5.23 | 18–292 |
[
|
| Prior cephalosporin exposure | 9 | OR | 4.51–7.60 | 17–88 |
[
|
| Other | 8 | OR | 1.66–9.30 | 18–94 |
[
|
| Patient characteristics | 3 | OR | 1.14–13.10 | 10–48 |
[
|
| 1 | HR | 1.57 | 206 |
[
| |
| Prior quinolone exposure | 3 | OR | 2.86–25.37 | 30–78 |
[
|
| Medical procedures | 2 | OR | 9.34–10.35 | 52–60 |
[
|
| Prior antifungal exposure | 2 | OR | 5.3–12 | 204 |
[
|
Abbreviations: RE, risk estimate, 2x, 3x, 4x or 6x, two, three, four or six different factors per reference.
a Bloodstream infections.
b This category was not included in a random-effects meta-analysis study.
Associated protective factors for the presence of ESBL-producing Klebsiella spp. based on multivariate analyses.
| Associated protective factor | No. of factors | No. of patients | RE | RE or RE Range | Studies |
|---|---|---|---|---|---|
| Medical devices | 2 | 206 | HR | 0.22–0.52 |
[
|
| Prior penicillin+ β lactamase inhibitor exposure | 2 | 88 | OR | 0.16–0.27 |
[
|
| Others | 2 | 27–292 | OR | 0.22–0.50 |
[
|
| Prior antibiotic exposure | 1 | 54 | OR | 0.003 |
[
|
| Prior carbapenem exposure | 1 | 206 | HR | 0.22 |
[
|
| Age | 1 | 47 | OR | 0.95 |
[
|
| Prior cephalosporin exposure | 1 | 204 | OR | 0.1 |
[
|
Abbreviations: RE, risk estimate; HR, hazard ratio; OR, odds ratio.
a This factor was classified in the category of prior antibiotic exposure for a random-effects meta-analysis study.
b This category was not included in a random-effects meta-analysis study.
c This factor was classified in the category of patient characteristics for a random-effects meta-analysis study.
Random-effects meta-analyses of the different associated risk factors and associated protective factors for the presence of ESBL-producing Klebsiella spp. among patients in hospitals.
| Associated factor | No. of factors | Pooled OR | 95% CI | Range of OR in individual studies | Risk of publication bias | |||
|---|---|---|---|---|---|---|---|---|
| Kendall's tau | P value | Egger | P value | |||||
| Underlying disease or condition | 9 | 6.25 | 2.85–13.66 | 1.66–60.60 | 0.39 | 0.18 | 2.61 | < 0.01 |
| Prior cephalosporin exposure | 9 | 4.65 | 2.83–7.65 | 0.10–7.60 | < 0.01 | 0.92 | − 2.26 | 0.14 |
| Prior other antibiotic exposure | 17 | 4.38 | 2.29–8.34 | 0.003–95.21 | 0.16 | 0.39 | 1.51 | 0.16 |
| Prior quinolone exposure | 3 | 3.91 | 1.83–8.34 | 2.86–25.37 | NC | NC | NC | NC |
| Medical devices | 9 | 2.99 | 2.27–3.95 | 2.11–5.23 | 0.33 | 0.26 | 1.53 | < 0.01 |
| Length of hospital stay | 8 | 1.16 | 1.06–1.27 | 1.05–12.60 | 0.55 | 0.08 | 3.25 | < 0.01 |
| Patient characteristics | 4 | 1.16 | 0.93–1.44 | 0.95–13.10 | < 0.01 | 0.75 | 4.11 | 0.18 |
Abbreviations: OR, odds ratio; CI, confidence interval; NC, not calculated because there were too few strata.
a Only studies included that reported 95% CI and P values
Fig 2Forest plots of random-effects meta-analyses: individual and pooled odds ratios for associated risk factors and associated protective factors for presence of ESBL-producing Klebsiella spp. among patients in hospitals.
* Bloodstream infections
Environmental sources and reservoirs for ESBL-producing Klebsiella spp., identified from n = 57 studies.
| Reservoirs or Sources | No of studies | Studies |
|---|---|---|
|
| ||
| Bottles | 1 |
[
|
| Door handles, a siphon and a table | 1 |
[
|
| Entire unit (Intensive Care Unit) | 2 |
[
|
| Hospital kitchen-screened surfaces | 1 |
[
|
| Incubator | 2 |
[
|
| Liquid soap | 2 |
[
|
| Mask | 1 |
[
|
| Moist surfaces near sinks and faucets | 1 |
[
|
| Roll boards in operating rooms | 1 |
[
|
| Room surface | 2 |
[
|
| Single use products | ||
| A. Intravenous medication or solution (re-used repeatedly) | 2 |
[
|
| B. Intravenous glucose preparation (multiple-dosed) | 1 |
[
|
| C. Oxygen saturation probes (re-used repeatedly) | 1 |
[
|
| Sinks | 4 |
[
|
| Suction pump located in the room of an infected patient | 1 |
[
|
| Suction tube | 1 |
[
|
| Thermometers | 2 |
[
|
| Two water reservoirs from humidifiers | 1 |
[
|
| Ultrasonography coupling gel container of the emergency room | 1 |
[
|
| Weighing scale machine for babies | 1 |
[
|
|
| ||
| Transient Hand Carriage | 1 |
[
|
| A. Patients | 23 |
[
|
| B. Health Care Workers | 4 |
[
|
| Food handlers | 1 |
[
|
| Handholding due to work overcharge | 1 |
[
|
| Hands | 11 |
[
|
| Artificial nails | 1 |
[
|
| Onychomycosis | 2 |
[
|
| C. Family (Mother to Child) | ||
| Breast milk | 2 |
[
|
| Peripartum colonization of neonates | 1 |
[
|
a This study proved the source or reservoir with use of a molecular typing technique.
Summary of studies (n = 120) reporting cluster analyses on identified ESBL-producing Klebsiella spp. using typing techniques.
| Methods | No. of Strains: | No. of Patterns: | No. of Clusters: | Cluster Size: | Unique Isolates | No of Studies | Studies | |
|---|---|---|---|---|---|---|---|---|
| Median (Range) | Median (Range) | Median (Range) | Median of Medians (Range of Median) | Median (Range) | ||||
|
| ||||||||
| A. | ||||||||
| PFGE | 25 (2–235) | 4 (1–55) | 2 (0–15) | 6 (0–81) | 2 (0–45) | 92 |
[
| |
| PCR | 24 (4–295) | 4 (1–125) | 1 (0–10) | 5.5 (1–87) | 2.5 (0–21) | 16 |
[
| |
| RAPD | 18 (8–40) | 3 (1–17) | 1 (1–4) | 11 (7–19) | 1 (0–15) | 7 |
[
| |
| MLST | 21.5 (1–46) | 2.5 (1–15) | 2 (0–3) | 2 (0–19) | 1 (0–13) | 7 |
[
| |
| Ribotyping | 18 (8–57) | 5.5 (1–15) | 2 (1–6) | 6 (2–14) | 2.5 (0–9) | 6 |
[
| |
| ME-AFLP | 8 (-) | 1 (-) | 1 (-) | 8 (-) | 0 (-) | 1 |
[
| |
| MLEE | 19 (-) | 11 (-) | 1 (-) | 9 (-) | 10 (-) | 1 |
[
| |
| B. | ||||||||
| PFGE | 2 (1–101) | 1 (1–27) | 1 (0–3) | 1 (0–8) | 1 (0–24) | 7 |
[
| |
| RAPD | 2 (-) | 1 (-) | 1 (-) | 2 (-) | 0 (-) | 1 |
[
| |
|
| ||||||||
| A. | ||||||||
| PFGE | 24.5 (18–31) | 2 (2–2) | 2 (1–2) | 11 (9–13) | 0 (0) | 3 |
[
| |
| RAPD | 37 (-) | 28 (-) | 6 (-) | 2 (-) | 22 (-) | 1 |
[
| |
| B. | ||||||||
| PFGE | 13 (3–23) | 5 (1–9) | 1 (0–2) | 3.5 (0–7) | 1 (1–1) | 2 |
[
| |
|
| ||||||||
|
| ||||||||
| PFGE | 49 (30–49) | 10 (2–25) | 7 (2–7) | 7 (2–15) | 3 (0–18) | 3 |
[
| |
| PCR | 39 (30–48) | 9.5 (2–17) | 3 (2–4) | 15 (-) | 6.5 (0–13) | 2 |
[
| |
| Raman spectroscopy | 30 (-) | 2 (-) | 2 (-) | 15 (-) | 0 (-) | 1 |
[
| |
Abbreviations: PFGE, pulsed-field gel electrophoresis; PCR, polymerase chain reaction (ERIC-PCR, enterobacterial repetitive intergenic consensus sequence; AP-PCR, arbitrarily primed-PCR; REP-PCR, repetitive sequence-based PCR; BOX-PCR; IRS-PCR, infrequent-restriction-site PCR; RFLP-PCR, restriction fragment length polymorphism); RAPD, random amplified polymorphic DNA; MLST, multi-locus sequence typing; ME-AFLP, multi-enzyme amplified fragment length polymorphism; MLEE, multilocus enzyme electrophoresis; (-), Only 1 study was reported
2x, This study performed two rounds of ERIC-PCR on a different dataset.
a We assessed the result of molecular typing methods and reported the total number of identified patterns as number of patterns
b Outbreak
c Monoclonal
d Polyclonal
e The number of patients were not literally written
f Number of clinical isolates for cluster analysis due to available data or different time points of the isolates
g Different presentation of data between text and figures on papers, hence we used data from the figures (except Liu 1998, Lavigne 2004, Wu 2006 and Cassettari 2009)
h MLST was only performed on the index patient
i Two publications used same isolates, hence, we combined the data
j This study was performed on 48 patient samples that consisted of 46 healthcare-related infections and 2 unidentified samples
k Data of number of patterns was not available
l Data of cluster size was not available
m Data of unique isolates was not available
n Data of unique isolates on the second round was not available.
Top 10 strategies to control ESBL-producing Klebsiella spp. outbreaks in hospitals.
| No. | Intervention | No. of studies | Studies |
|---|---|---|---|
| 1 | Reinforcement of hand hygiene | 33 |
[
|
| 2 | Control of antibiotic use | 24 |
[
|
| 3 | Strict hygienic practices | 18 |
[
|
| 4 | a. Screening programs with an active microbiological surveillance | 15 |
[
|
| b. Cohorting of patients | 15 |
[
| |
| 5 | Single-use equipment | 14 |
[
|
| 6 | Barrier precautions | 12 |
[
|
| 7 | Patient isolation | 11 |
[
|
| 8 | Good cooperation between department and infection control team | 9 |
[
|
| 9 | Personnel educational programs | 8 |
[
|
| 10 | a. Removal of contaminated tools | 7 |
[
|
| b. Temporary closure of contaminated rooms | 7 |
[
| |
| c. Medical-equipment disinfections | 7 |
[
|
a The study added this additional intervention that was successful to control the events of ESBL-producing Klebsiella spp. in the hospital.